ストックスクリーナーアプリを入手
14.71
12.23%
-2.05
アフターアワーズ：
15.00
0.29
+1.97%
前日終値:
$16.76
開ける：
$16.96
24時間の取引高:
6.75M
Relative Volume:
3.80
時価総額：
$2.03B
収益：
$181.74M
当期純損益:
$-143.97M
株価収益率:
-10.58
EPS:
-1.39
ネットキャッシュフロー:
$9.60M
1週間 パフォーマンス:
-20.96%
1か月 パフォーマンス:
-3.98%
6か月 パフォーマンス:
-25.56%
1年 パフォーマンス:
-48.02%
1日の値動き範囲:
$14.32
$17.00
1週間の範囲:
$14.32
$19.32
52週間の値動き範囲:
$9.57
$29.86
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
ARWR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
14.71 | 2.57B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
What drives Arrowhead Pharmaceuticals Inc. stock priceFree Stock Market Return Analysis - Autocar Professional
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - Yahoo Finance
What analysts say about Arrowhead Pharmaceuticals Inc. stockExceptional profit velocity - Autocar Professional
Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha
Arrowhead Pharmaceuticals Plummets 9.4%: A Bearish Surprise in Biotech's RNAi Frontier - AInvest
Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional
Is Arrowhead Pharmaceuticals Inc. a good long term investmentExceptional growth trajectory - jammulinksnews.com
Insiders At Arrowhead Pharmaceuticals Sold US$3.1m In Stock, Alluding To Potential Weakness - simplywall.st
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia - TipRanks
Arrowhead Pharmaceuticals (ARWR) Soars 7.64% on Clinical Trial Advances - AInvest
Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management - TipRanks
Arrowhead Pharmaceuticals' Zodasiran: A Pioneering ANGPTL3 Inhibitor for HoFH and Beyond - AInvest
Arrowhead Pharmaceuticals initiates phase 3 Yosemite study of investigational zodasiran - MarketScreener
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire
Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse - The Globe and Mail
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire
Where are the Opportunities in (ARWR) - news.stocktradersdaily.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada
California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey
Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire
Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com
What is HC Wainwright’s Estimate for ARWR FY2025 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead at RBC Conference: Strategic Insights on Drug Pipeline By Investing.com - Investing.com India
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World
B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World
Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):